In March 2025, the European Commission proposed new legislation called the Critical Medicines Act (CMA). Its main goals are straightforward: to strengthen the availability and security of supply of critical medicines in the EU, and to ensure fair access to vital medicines through coordinated action at EU and national levels. For people with CF, medicine […]
Month: December 2025
European Lung Health Group: Advancing Respiratory Policy and Patient Advocacy
A focus on the European Lung Health Group Over the past years, the European Lung Health Group (ELHG) has established its role as a key platform for coordination, advocacy, and political engagement on lung health at the EU level. Bringing together patient organisations, scientific societies, and policy stakeholders, ELHG shapes a unified European agenda focused […]
HIT-CF news: Promising results of the CHOICES CFTR modulator trial !
They are finally here: the HIT-CF team shares promising results of the CHOICES CFTR modulator trial and they suggest a good match between organoid testing and clinical outcomes! This text is a community adaption of the original press release of October 20, 2025. In October, the HIT-CF team has presented the final results of its major […]
European Respiratory Patient Academy in Prague: Empowering Our Community Through the European Respiratory Patient Academy
Empowering Our Community Through the European Respiratory Patient Academy In November, five advocates from CF Europe member organisations joined 42 participants from 23 countries at the European Respiratory Patient Academy—four intensive days focused on turning lived experience into policy change. The Polish Society for the Fight Against Cystic Fibrosis, ASSOCIATION MUCOVISCIDOSIS Bulgaria, Slovak Cystic Fibrosis […]